Navigation Links
SuperGen to Announce 2008 Third Quarter Financial Results November 4, 2008
Date:10/28/2008

DUBLIN, Calif., Oct. 28 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that it will release its 2008 third quarter financial results on Tuesday, November 4, 2008. SuperGen's management team will provide details of the Company's financial results and any revised outlook for the future.

A press release will be transmitted to the news media immediately following the close of the market on November 4th. The Company will host a conference call and webcast to discuss the results at 4:30 p.m. ET / 1:30 p.m. PT. The webcast will be accessible via the Investor Relations section of the Company's Web site at http://www.supergen.com. A webcast replay of the live conference call will be available shortly following the event. Alternatively, you may access a replay of the conference call by dialing 1-888-286-8010 (domestic) and 1-617-801-6888 (international); replay passcode number is 37633541. The webcast replay and conference call replay will be available for 90 days.

About SuperGen

Based in Dublin, Calif., SuperGen Inc. is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Contacts:

SuperGen, Inc.

Timothy L. Enns

SVP, Corporate Communications & Business Development

Tel: (925) 560-0100

Email: tenns@supergen.com

Mary M. Vegh

Manager, Investor Relations

Tel: (925) 560-2845

E-mail: mary.vegh@supergen.com

Dorland Global Public Relations

Michael Beckerich (Media)

Tel: (212) 677-7632

mbeckerich@dorland.com


'/>"/>
SOURCE SuperGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SuperGens MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy
2. SuperGen to Present Data at EORTC-NCI-AACR
3. SuperGen to Present at Merriman 5th Annual Investor Summit on September 15, 2008
4. SuperGen Reports 2008 Second Quarter Financial Results
5. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
6. SuperGen Reports 2008 First Quarter Financial Results
7. SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
8. SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008
9. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
10. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
11. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Minn. , Dec. 7, 2016  Vyriad Inc. ... to the company,s Board of Directors. ... as we build our business and develop our oncolytic ... cancer therapy," said Stephen Russell , MD, PhD, ... Agnes , share our vision and passion for making ...
(Date:12/7/2016)... 7, 2016  Genprex, Inc. a biopharmaceutical company ... treatments, today announced that it has retained ICR ... strategic communications and advisory firm, to develop and ... will combine investor relations, public relations and digital ... profile of Genprex and its lead candidate Oncoprex, ...
(Date:12/7/2016)... , Dec. 7, 2016  Muse bio, a ... technologies, today announced that Dr. Kevin Ness ... the Board of Directors. Kevin succeeds ... becomes the company,s Chief Science Officer as well as ... Director of the BioDesign Center at the RAS Energy ...
(Date:12/7/2016)... NEW YORK and ANN ARBOR, ... a privately held biopharmaceutical company developing breakthrough immune modulatory ... clinical trial of the Company,s lead therapeutic candidate, LYC-30937- ... Psoriasis is often a debilitating skin disease that is ... the United States , with approximately ...
Breaking Biology Technology:
(Date:12/7/2016)... , Dec. 7, 2016   Veridium ... announced the appointment of new CEO James ... executive with decades of experience, has served in ... Cisco, where he specialized in expanding a pipeline ... technology portfolios. He most recently served as managing ...
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE ... priced an offering of €500.0 million principal amount of its ... amount of its 2.425% senior unsecured notes due 2026. ... occur on December 13, 2016, subject to the satisfaction of customary ... basis. The Company intends to ...
(Date:12/6/2016)... Valencell , the leading innovator in ... a third consecutive year of triple digit growth for ... with a 360 percent increase in companies who have ... driven by sales of its wrist and ear Benchmark™ ... technology for hearables for fitness and healthcare applications. ...
Breaking Biology News(10 mins):